Risk Management and Healthcare Policy (Jun 2025)
Transforming Opioid Overdose Prevention in the United States: Leveraging FDA’s Narcan Approval to Foster a Culture of Health
Abstract
Pavani Rangachari, Alvin Tran Department of Population Health and Leadership, University of New Haven, West Haven, CT, USACorrespondence: Pavani Rangachari, Department of Population Health and Leadership, University of New Haven, 300 Boston Post Road, West Haven, CT, USA, Email [email protected]: The opioid crisis in the United States remains a major public health emergency, claiming over 100,000 lives annually, with potent synthetic opioids like fentanyl driving the surge in overdose deaths. In response, the US Food and Drug Administration’s (FDA) approval of over-the-counter (OTC) Narcan represents a pivotal step toward expanding access to naloxone, a life-saving medication that reverses opioid overdoses. However, maximizing the public health impact of this measure requires more than increasing availability—it demands a comprehensive, systemic approach that fosters community engagement, advances harm reduction, and transforms healthcare delivery. This paper applies the Robert Wood Johnson Foundation’s (RWJF) Culture of Health (COH) model to provide a structured framework for optimizing Narcan’s impact. Through its four interconnected pillars, (1) making health a shared value, (2) fostering cross-sector collaboration, (3) ensuring equitable access, and (4) transforming healthcare systems, the COH model offers critical insights into building sustainable, community-wide overdose prevention strategies. Central to this effort is stigma reduction, as negative perceptions of opioid use disorder continue to undermine both public willingness to seek naloxone and healthcare providers’ readiness to offer it. Within the COH framework, the paper examines evidence-based interventions that normalize naloxone use, innovative cross-sector partnerships that foster acceptance, and policy initiatives that expand access while addressing systemic inequities. By synthesizing real-world success stories, including community-based naloxone distribution programs, law enforcement-assisted interventions, and hospital-based harm reduction initiatives, this paper outlines a strategic blueprint for translating the FDA’s Narcan ruling into lasting public health outcomes. It concludes with actionable recommendations for healthcare systems, policymakers, and public health agencies to institutionalize harm reduction practices and dismantle barriers to care. Only by embedding a Culture of Health into the fabric of healthcare, public health, and community systems can we achieve lasting progress against the opioid crisis and foster healthier, more equitable communities.Keywords: opioid crisis, naloxone access, harm reduction, Narcan, culture of health model, substance use disorder, overdose prevention, health equity
